Hjem › Ikke-småcellet lungekreft › Illinois › Chicago
Kliniske studier for Ikke-småcellet lungekreft i Chicago, IL
61 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Chicago (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- og 1 flere
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RekruttererFase 3
- The University of Chicago Medical Center ( Site 0118), Chicago
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
RekruttererFase 3
- University of Illinois Cancer Center, Chicago
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RekruttererFase 2
- Rush MD Anderson Cancer Center, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- University of Chicago Hospital, Chicago
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #26, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekruttererFase 2
- University of Illinois Cancer Center, Chicago
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Northwestern University, Chicago
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RekruttererFase 3
- University of Chicago Medical Center, Chicago
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RekruttererFase 3
- University of Illinois Cancer Center, Chicago
- Center for Care and Discovery, Chicago
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekruttererFase 3
- Illinois Cancer Specialists, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruttererFase 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RekruttererFase 3
- University of Illinois Chicago, Chicago
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RekruttererFase 1
- Research Site, Chicago
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekruttererFase 2
- Rush University Medical Center Rush University Cancer Center Chicago, Chicago
- University of Illinois at Chicago, Chicago
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekruttererFase 2
- Rush University Medical Center, Chicago
- University of Illinois Chicago, Chicago
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RekruttererFase 3
- Research Site, Chicago
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RekruttererFase 3
- City of Hope, Chicago, Chicago
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RekruttererFase 2
- Research Site, Chicago
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
RekruttererFase 2
- University of Illinois Hospital and Health Sciences System /ID# 275345, Chicago
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RekruttererFase 2/3
- Rush University Medical Center, Chicago
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RekruttererFase 3
- University of Illinois at Chicago, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruttererFase 1
- Northwestern University Feinberg School of Medicine, Chicago
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RekruttererFase 3
- Research Site, Chicago
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekruttererFase 3
- Clinical Study Site, Chicago
- Clinical Study Site, Chicago
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
RekruttererFase 3
- Northwestern University, Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekruttererFase 2/3
- University of Chicago, Chicago
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
RekruttererFase 2/3
- The University of Chicago Medical Center /ID# 262259, Chicago
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
RekruttererFase 2
- Northwestern University, Chicago
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruttererFase 1
- University of Chicago, Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekruttererFase 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RekruttererFase 1
- Northwestern University, Chicago
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RekruttererFase 3
- Research Site, Chicago
- Research Site, Chicago
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
RekruttererFase 3
- University of Chicago Medical Center ( Site 0145), Chicago
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RekruttererFase 3
- University of Illinois Hospital and Health Sciences Systems, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekruttererFase 3
- Northwestern University, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
RekruttererFase 1/2
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RekruttererFase 1/2
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
RekruttererFase 1/2
- University of Chicago, Chicago
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RekruttererFase 3
- Northwestern University, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruttererFase 1
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
RekruttererFase 1
- The University of Chicago Medical Center (UCMC), Chicago
Study of XB010 in Subjects With Solid Tumors
RekruttererFase 1
- University of Chicago Medical Center, Chicago
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
RekruttererFase 2
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RekruttererFase 1/2
- Northwestern Memorial Hospital, Chicago
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
Rekrutterer
- Northwestern University, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RekruttererFase 1/2
- University of Chicago, Chicago
Segmentectomy After Induction Therapy (SAINT)
Rekrutterer
- Northwestern University, Chicago
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruttererFase 3
- Research Site, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
RekruttererFase 2
- University of Illinois Cancer Center, Chicago
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekruttererFase 1/2
- Northwestern Memorial Hospital, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruttererObservasjonsstudie
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Rekrutterer
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
RekruttererFase 1
- University of Chicago, Chicago
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
RekruttererObservasjonsstudie
- University of Chicago, Chicago
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY120 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH56 studier
- Washington, DC55 studier
- Seattle, WA53 studier
Andre studier i Chicago
- Brystkreft58 studier
- Kreft (alle typer)51 studier
- Metastatisk kreft45 studier
- Prostatakreft45 studier
- Fedme41 studier
- Lungekreft41 studier
- Eggstokkreft36 studier
- Slag34 studier
- Kolorektal kreft33 studier
- Hjertesvikt31 studier
- Overvekt28 studier
- Plateepitelcancer i hode og hals26 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.